Literature DB >> 23448847

Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.

Leslie Citrome1.   

Abstract

Antipsychotics are the mainstay of treatment for patients with schizophrenia. However, these medications only work if they are taken and perhaps work best if they are taken for longer periods of time than seen in typical research trials. Here we explore the idea of "time as drug" by reviewing the data showing the potential benefits of long-term antipsychotic use. We also discuss the utility of depot antipsychotic formulations for improving the chances of attaining long-term therapeutic results.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23448847     DOI: 10.1017/S1092852912000727

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  4 in total

Review 1.  A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.

Authors:  Leslie Citrome
Journal:  CNS Drugs       Date:  2013-11       Impact factor: 5.749

2.  [Risk factors for treatment adherence in patients with schizophrenia: case-control study].

Authors:  Chadya Aarab; Fatima Elghazouani; Rachid Aalouane; Ismail Rammouz
Journal:  Pan Afr Med J       Date:  2015-03-20

Review 3.  Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.

Authors:  Peng Li; Gretchen L Snyder; Kimberly E Vanover
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

4.  A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.

Authors:  Andy Forbes; Mary Hobart; John Ouyang; Lily Shi; Stephanie Pfister; Mika Hakala
Journal:  Int J Neuropsychopharmacol       Date:  2018-05-01       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.